U.S FDA approved new medicine siliq that contains active drug brodalumab for the treatment of psoriasis in adults. Psoriasis is a common auto-immune disorder in among all populations. Psoriasis might be of different types like plaque psoriasis, guttate psoriasis, erythrodermic psoriasis, inverse psoriasis and postular psoriasis. FDA approved Siliq for moderate to severe plaque psoriasis in adults.
Plaque psoriasis is basically a skin disorder that intense irritation and itching on skin and leaves the skin scaly or flaky along with reddish color appearance of skin. This condition may occur without regard to gender, age or ethnicity. However, it is commonly observed that people who have family history of plaque psoriasis or other are more prone to get involved in such disorder.
Siliq/brodalumab belongs to a group termed as monoclonal antibody. Basic mechanism by which brodalumab targets plaque psoriasis is that it binds to receptor interleukin-17 that generates inflammatory mediators to aggravate plaque psoriasis. Interleukin-17 does not activate after binding to brodalumab making it unable to release inflammatory mediators to make condition worse.
Siliq/brodalumab Side effectsDuring clinical trials drug exhibit some side effects or adverse effects experience by adult participants. These side effects were moderate to severe e.g
- Joint pain (arthralgia)
- Injection site reactions
- low white blood cell count (neutropenia)
- Fungal (tinea) infections
- Throat pain (oropharyngeal pain)
- Nausea, muscle pain (myalgia)
- Suicidal tendency